Geographical/Interracial Differences in Polymorphic Drug Oxidation: Current State of Knowledge of Cytochromes P450 (CYP) 2D6 and 2C19

Clinical Pharmacokinetics

Volumn 29, Issue 3, 1995, Pages 192-209

  Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; CYTOCHROME P450; DEBRISOQUINE; DIAZEPAM; MEPHENYTOIN; NEUROLEPTIC AGENT; OMEPRAZOLE; PROLINE; SERINE; SPARTEINE;

ALLELE; AMINO ACID SUBSTITUTION; CAUCASIAN; DEMETHYLATION; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG OXIDATION; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; MOLECULAR GENETICS; MONGOLOID RACE; NEGRO; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DIAZEPAM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GEOGRAPHY; HUMANS; MIXED FUNCTION OXYGENASES; MUTATION; OMEPRAZOLE; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY;

EID: 0029028932     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199529030-00005     Document Type: Review

References (103)

1. Ethnic differences in drug metabolism
2. Interethnic factors affecting drug response
3. Ethnic differences in drug disposition and responsiveness
4. Differences in drug metabolism polymorphisms between Orientals and Caucasians
5. Interindividual and interethnic differences in polymorphic drug oxidation — implications for drug therapy with focus on psychoactive drugs
6. Genetic factors in drug therapy
7. Human genetics
8. Genetic relationship of human populations and ethnic differences in reactions to drugs and food
9. Pharmacoanthropology and the genetics of drug metabolism
10. Human cytochromes P450: problems and prospects
11. The molecular genetics of the human drug metabolizing cytochrome P450s
12. Polymorphic hydroxyla-tion of debrisoquine in man
13. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect
14. Polymorphic oxidation of sparteine and debrisoquine. Related pharmacogenetic entities
15. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Janpaneses population
16. Dissociation of coregulatory control of debrisoquine/phenformin and sparteine oxidation in Ghanians
17. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population
18. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
19. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin
20. The genetic polymorphism of debriosquine/sparteine metabolism — clinical aspects
21. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
22. Relationship between personality and debrisoquine hydroxylation capacity — suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6
23. Low frequency of slow debrisoquine hydroxylation in a native Chinese population
24. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population
25. Metoprolol and debrisoquine metabolism in Nigerians: lack of evidence for polymorphic oxidation
26. Interethnic variation of drug metabolism
27. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda
28. Chromosomal assignment of human cytochrome P450 (debrisoquine/sparteine type) to chromosome 22
29. Two mutant alleles of the human cytochrome P450 dbl gene (P450 II Dl) associated with genetically deficient metabolism of debrisoquine and other drugs
30. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism
31. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6
32. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
33. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population
34. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population
35. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine
36. Genetic analysis of the Chinese CYP2D6 locus. Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
37. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6
38. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans
39. Genetic polymorphism of cytochrome P450 2D6 in Zimbabwean population
40. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine
41. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese
42. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism
43. Extremely rapid hydroxylation of debrisoquine — a case report with implication for treatment with nortriptyline and other tricyclic antideprassants
44. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
45. Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine
46. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
47. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes
48. A predictive model for substrates of cytochrome P450-debrisoquine (2D6)
49. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine
50. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine
51. Hydroxylation of des-methyldesipramine dependence on the debrisoquin hydroxylation phenotype
52. Desipramine pharmacokinetics in Chinese and Caucasian volunteers
53. Pharmacokinetic and other related factors affecting psychotropic responses in Asians
54. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers
55. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate
56. Genetically variable metabolism of antidepressants and neuroleptic drugs in man
57. Pharmacogenetic factors in the metabolism of tricyclic antidepressants and some neuroleptics
58. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms
59. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test
60. Neuroleptic dosage for Asians
61. Haloperidol concentrations elevated in Chinese patients
62. Haloperidol and prolactin concentrations in Asians and Caucasians
63. Debrisoquine hydroxylation polymorphism and personality
64. Debrisoquine/sparteine monooxygenase and other P450s in brain
65. The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxyl-ase) in brain: resolution and identification of two distinct [3H] GBR-12935 binding proteins
66. Role of genetic polymorphism in psychopharmacology — an update
67. Stereoselective metabolism, pharmacokinetics and biliary elimination of phenylethyl-hydantoin (Nirvanol) in the dog
68. Family study of a genetically determined deficiency of mephenytion hydroxylation in man
69. Genetic polymorphism of S-mephenytoin hydroxylation
70. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism
71. S-mephenytoin hydroxylation phenotype in a Swedish population — determined after co-administration with debrisoquin
72. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio
73. Pharmacogenetic association between the formation of 4-hydroxy-mephenytoin and a new metabolite of S-mephenytoin in man
74. Genetic polymorphism of mephenytoin p(4′)hydroxylation: difference between Orientals and Caucasians
75. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese
76. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics
77. S-mephenytoin 4-hy-droxylation in older Americans
78. Phenotyping and genotyping of S-mephenytoin hydroxylase (Cytochrome P450 2C19) in a Shona population of Zimbabwe
79. Biochemistry and molecular biology of the human CYP2C subfamily
80. Isolation and characterization of human liver cytochrome P4502C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation
81. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans
82. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
83. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
84. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine
85. Propranolol’s metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities
86. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism — a panel study
87. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase
88. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin but not debrisoquin hydroxylation phenotype
89. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects
90. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics
91. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations, but not in Chinese populations?
92. Diazepam effect and kinetics in Caucasians and Orientals
93. Differences in diazepam pharmacokinetics in Chinese and white Caucasians — relation to body lipid stores
94. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers
95. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
96. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolisers of omeprazole
97. Slow omeprazole metabolisers are also poor S-mephenytoin hydroxylators
98. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects
99. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolisers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population
100. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals
101. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19